Total Payments
$15,681
2024 Payments
$1,223
Companies
56
Transactions
846
Medicare Patients
3,867
Medicare Billing
$525,122
Payment Breakdown by Category
Food & Beverage$14,864 (94.8%)
Education$817.36 (5.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,864 | 814 | 94.8% |
| Education | $817.36 | 32 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,315 | 83 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,149 | 66 | $0 (2024) |
| Amgen Inc. | $1,070 | 51 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,028 | 64 | $0 (2024) |
| Genentech USA, Inc. | $944.03 | 64 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $939.16 | 48 | $0 (2024) |
| PFIZER INC. | $922.86 | 68 | $0 (2024) |
| Celgene Corporation | $864.79 | 40 | $0 (2023) |
| Janssen Biotech, Inc. | $844.88 | 53 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $736.70 | 33 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,223 | 51 | GENZYME CORPORATION ($260.75) |
| 2023 | $720.23 | 34 | GENZYME CORPORATION ($125.27) |
| 2022 | $212.50 | 10 | Amgen Inc. ($56.37) |
| 2021 | $30.56 | 2 | Novartis Pharmaceuticals Corporation ($18.46) |
| 2020 | $2,414 | 138 | E.R. Squibb & Sons, L.L.C. ($270.75) |
| 2019 | $3,440 | 193 | Merck Sharp & Dohme Corporation ($327.12) |
| 2018 | $3,679 | 212 | Amgen Inc. ($458.78) |
| 2017 | $3,962 | 206 | Genentech USA, Inc. ($451.69) |
All Payment Transactions
846 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $28.48 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $1.18 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $36.99 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.71 | General |
| Category: Oncology | ||||||
| 11/19/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $36.99 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $13.60 | General |
| 11/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $30.57 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: Oncology | ||||||
| 10/22/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 10/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $21.02 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $38.88 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.87 | General |
| 09/24/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: ONCOLOGY | ||||||
| 08/06/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Oncology | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: Oncology | ||||||
| 07/29/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Oncology | ||||||
| 07/22/2024 | PFIZER INC. | INLYTA (Drug), TALZENNA, XTANDI | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 329 | 668 | $184,752 | $57,576 |
| 2022 | 6 | 361 | 748 | $213,503 | $75,509 |
| 2021 | 6 | 355 | 592 | $126,445 | $50,965 |
| 2020 | 43 | 2,822 | 124,525 | $1.0M | $341,072 |
Total Patients
3,867
Total Services
126,533
Medicare Billing
$525,122
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 136 | 340 | $77,412 | $23,324 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 100 | 220 | $70,030 | $22,198 | 31.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $16,190 | $4,417 | 27.3% |
| 99236 | Initial hospital care with same-day admission and discharge with high level of medical decision making, per day, if using time, at least 85 minutes | Facility | 2023 | 23 | 25 | $12,250 | $3,997 | 32.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 26 | $5,720 | $2,368 | 41.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 21 | $3,150 | $1,271 | 40.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 138 | 453 | $137,095 | $51,003 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 110 | 161 | $34,128 | $10,169 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 43 | 43 | $18,671 | $5,692 | 30.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 25 | $10,716 | $3,887 | 36.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 47 | $10,115 | $3,694 | 36.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 19 | $2,778 | $1,064 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 127 | 273 | $49,985 | $20,437 | 40.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 49 | 82 | $21,999 | $9,259 | 42.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 50 | 50 | $17,210 | $6,392 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 42 | 69 | $14,145 | $5,637 | 39.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 49 | 50 | $13,450 | $5,374 | 40.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 68 | $9,656 | $3,866 | 40.0% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2020 | 18 | 29,501 | $191,757 | $87,976 | 45.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2020 | 55 | 80,250 | $160,500 | $70,817 | 44.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 296 | 746 | $130,550 | $55,386 | 42.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 27 | 297 | $119,097 | $31,621 | 26.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 60 | 60 | $21,000 | $7,785 | 37.1% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 19 | 601 | $30,050 | $7,536 | 25.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2020 | 247 | 676 | $48,334 | $7,080 | 14.6% |
About Dr. John Weinhold, MD
Dr. John Weinhold, MD is a Medical Oncology healthcare provider based in Olean, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1265417737.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Weinhold, MD has received a total of $15,681 in payments from pharmaceutical and medical device companies, with $1,223 received in 2024. These payments were reported across 846 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($14,864).
As a Medicare-enrolled provider, Weinhold has provided services to 3,867 Medicare beneficiaries, totaling 126,533 services with total Medicare billing of $525,122. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Olean, NY
- Active Since 12/07/2005
- Last Updated 06/01/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1265417737
Products in Payments
- KEYTRUDA (Biological) $1,083
- OPDIVO (Biological) $1,002
- Imbruvica (Drug) $678.47
- Abraxane (Drug) $405.73
- JAKAFI (Drug) $393.49
- SARCLISA (Biological) $366.33
- IMBRUVICA (Drug) $357.33
- Neulasta (Biological) $341.33
- Rubraca (Drug) $330.97
- DARZALEX (Biological) $317.36
- KISQALI (Drug) $309.44
- Revlimid (Drug) $308.31
- TAGRISSO (Drug) $307.28
- XTANDI (Drug) $283.57
- GILOTRIF (Drug) $278.35
- TECENTRIQ (Biological) $246.30
- INJECTAFER (Drug) $229.84
- Kyprolis (Drug) $224.60
- Avastin (Biological) $221.41
- IMFINZI (Drug) $219.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.